Background Case-reports/series and cohorts of Guillain–Barré syndrome (GBS) associated
with COVID-19 vaccination have been reported. Methods A systematic review and meta …

Background Coronavirus disease 2019 (COVID-19) pandemic scared the whole world at the
end of 2019, which is a communicable respiratory disease caused by severe acute …

Abstract The vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) is an important public health strategy to prevent people from the pandemic. Vaccines …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), broke out in 2019 and became a pandemic in 2020. Since …

There are limited published data within sub-Saharan Africa describing hospital pathways of
COVID-19 patients hospitalized. These data are crucial for the parameterisation of …

Objective To assess the rates of vascular thrombotic adverse events in the first 35 days after
one dose of the Ad26. COV2. S vaccine (Janssen/Johnson & Johnson) in healthcare …

Background COVID-19 vaccine coverage remains low in many low and middle-income
countries despite widespread access. To understand the dynamic decision-making process …

Objective To summarize the primary data sources used in constructing benchmark
databases for adverse drug reactions (ADR) and to demonstrate a comprehensive, multi …

The Sisonke 2 study provided a homologous boost at least 6 months after administration of
the priming dose of Ad26. COV2. S for healthcare workers enrolled on the Sisonke phase 3b …

Background Reactogenicity informs vaccine safety, and may influence vaccine uptake. We
evaluated factors associated with reactogenicity in HVTN 702, a typical HIV vaccine efficacy …